Topics

Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

01:18 EDT 16 Aug 2019 | ChinaBio Today

Nanjing Frontier Biotechnologies was approved to stage a $285 million IPO on the Shanghai STAR Exchange. Frontier has a China approved treatment for HIV, and it is developing another HIV treatment that it in-licensed from the Rockefeller University of New York City. Founded in 2002 by returnees, Frontier has developed a long-acting peptide drug discovery-development platform that is designed to transform any peptide drug into a long-acting agent. Frontier is developing its own drugs, but it also offers its platform to outside companies to develop long-acting formulations. More details....

Share this with colleagues:

Original Article: Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange

NEXT ARTICLE

More From BioPortfolio on "Nanjing Frontier Biotech Plans $285 Million IPO on Shanghai STAR Exchange"

Quick Search

Relevant Topics

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

AIDS and HIV
AIDS; Acquired Immune Deficiency Syndrome. HIV; Human Immunodeficiency Virus HIV infection causes AIDS. HIV infection also causes the production of anti-HIV antibodies, which forms the test for HIV in patients. People who have the HIV antibodies are ...